---
title: CpG island methylator phenotype classification improves risk assessment in
  pediatric T-cell Acute Lymphoblastic Leukemia
date: '2025-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39841000/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250123170657&v=2.18.0.post9+e462414
source: Blood
description: 'Current intensive treatment of pediatric T-cell acute lymphoblastic
  leukemia (T-ALL) has substantial side-effects, highlighting a need for novel biomarkers
  to improve risk stratification. Canonical biomarkers such as genetics and immunophenotype
  are largely not used in pediatric T-ALL stratification. This study aimed to validate
  the prognostic relevance of DNA methylation CpG island methylator phenotype (CIMP)
  risk stratification in two pediatric T-ALL patient cohorts: the Nordic NOPHO ...'
disable_comments: true
---
Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side-effects, highlighting a need for novel biomarkers to improve risk stratification. Canonical biomarkers such as genetics and immunophenotype are largely not used in pediatric T-ALL stratification. This study aimed to validate the prognostic relevance of DNA methylation CpG island methylator phenotype (CIMP) risk stratification in two pediatric T-ALL patient cohorts: the Nordic NOPHO ...